Form PTO-1349

U.S. Department of Commerce
Ratent and Trademark Office

Information Disciplinative Statement Substitute Form PTO-1449 (Modified)

Attorney's Docket No. 10287-051001

Application No. 09/536,087 RECEIVED

JAN 31 2001

TECH CENTER 1600/2900

by Applicant (Use several sheets if necessary) Applicant

Michael Detmar et al.

(37 CFR §1.98(b))

J.

Filing Date March 24, 2000 Group Art Unit

| | | | U.S. Pate | nt Documents | | | |
|---------------------|--------------|------------------|------------|--------------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | | | | | | | |
| | | | | | | | |

| | Foreig | n Patent Doo | uments or Pu | blished Foreign | Patent A | Applicatio | ns | - |
|----------|--------|--------------|--------------|-----------------|----------|------------|---------|------|
| Examiner | Desig. | Document | Publication | Country or | | | Transla | tion |
| Initial | ID | Number | Date | Patent Office | Class | Subclass | Yes | No |
| | | | | | | | | |
| | | | | | | | ļ | |
| | | | | | | | | |

| | Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
|-----------------|---|--|--|--|--|--|
| Examiner Desig. | | , | | | | |
| Initial ID | | Document | | | | |
| 100 | AA | Dawson, David W. et al., CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on | | | | |
| NAD | AA | Endothelial Cells, Journal of Cell Biology, Vol. 138, No. 3 (1997) 707-717 | | | | |
| Λ | AB | Hanahan, Douglas et al., Patterns and Emerging Mechanisms of the Angiogenic Switch during | | | | |
| 1 | AD | <u>Tumorigenesis</u> , Cell, Vol. 86 (1996) 353-364 | | | | |
| | | Brown, L.F. et al., Vascular permeability factor/vascular endothelial growth factor: A | | | | |
| | AC | Multifunctional Angiogenic cytokine, Regulation of Angiogenesis, (1997) Birkhäuser Verlag | | | | |
| · | | Basel/Switzerland • | | | | |
| | AD | Ferrara, Napoleone, The role of vascular endothelial growth factor in pathological angiogenesis, | | | | |
| | AD | Breast Cancer Research and Treatment, No. 36 (1995) 127-137 | | | | |
| | | Claffey, Kevin P., et al., Expression of Vascular Permeability Factor/Vascular Endothelial Growth | | | | |
| | AE | Factor by Melanoma Cells Increases Tumor Growth, Angiogenesis, and Experimental Metastasis, | | | | |
| | | Cancer Research, Vol. 56, 1 (1996) 1-233 | | | | |
| AF | | Sckobe, Michael, et al., Halting Angiogenesis Suppresses Carcinoma Cell Invasion, Nature | | | | |
| | | Medicine, Vol. 3, 11 (1997) 1222-1227 | | | | |
| | AG | Iruela-Arispe, M. Luisa et al., <u>Thrombospondin Exerts an Antiangiogenic effect on cord formation</u> | | | | |
| · | 710 | by endothelial cells in vitro, Proc. Natl. Acad. Sci. USA, Vol. 88 (1991) 5026-5030 | | | | |
| | AH | O'Reilly, Michael S. et al., Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the | | | | |
| | 7111 | Suppression of Metastases by a Lewis Lung Carcinoma, Cell, Vol. 79 (1994) 315-328 | | | | |
| | l _{AI} | O'Reilly, Michael S et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor | | | | |
| | Ai | <u>Growth</u> , Cell, Vol. 88 (1997) 277-285 | | | | |
| | AJ | Bornstein, Paul, <u>Diversity of Function is Inherent in Matricellular Proteins: An Appraisal of</u> | | | | |
| | AJ | Thrombospondin 1, Journal of Cell Biology, Vol. 130, 3 (1995) 503-506 | | | | |
| | AK | Tolsma, Sara S. et al., <u>Thrombospondin-1 Have Anti-Angiogenic Activity</u> , <i>Journal of Cell Biology</i> , | | | | |
| AK | | Vol. 122, 2 (1993) 497-511 | | | | |
| | AL | Goodson, Robert J. et al., High Affinity Urokinase Receptor Antagonists Identified with | | | | |
| | AL | Bacteriophage Peptide Display, Proc. of the Natl. Acad. of Sci. USA, Vol. 91, 15 (1994) 7129-7133 | | | | |
| 4) | AM | Seimeister, Gerhard et al., The Pivotal Rose of VEGF in Tumor Angiogenesis: Molecular Facts and | | | | |
| | YIVI | Therapeutic Opportunities, Cancer and Metastasis Reviews, Vol. 17 (1998) 241-248 | | | | |

| Examiner Signature | 1/ | Eli | St | 20 | |
|--------------------------|----|-----|----|----|--|
| E344 5 415 1 E 5 1 1 1 1 | | | | | |

Date Considered

2-18-02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | 1 2 9 2011 H | | Sheet <u>2</u> of <u>2</u> | | | |
|--|--------------|---|--|--|--|--|--|
| Substitute Form (Modified) | n PT 21449 | Patent and Trademark Office | Attorney's Docket No. 10287-051001 | Application No. 09/536,087 | | | |
| In | | by Applicant | Applicant Michael Detmar et al. | Application No. 09/536,087 | | | |
| (37 CFR §1.98 | | veral sheets if necessary) | Filing Date March 24, 2000 | Group Art Unit TECH CENTER 1500 F Publication) | | | |
| | | | | - 1600/200n | | | |
| | | ocuments (include Author, 1 | fitle, Date, and Place o | f Publication) | | | |
| Examiner Initial | Desig. ID | | Document | | | | |
| NAD | AN | Bornstein, Paul, <u>Thrombospondins:</u> 9 Vol. 6, 14 (1992) 3290-3298 | | • | | | |
| | AO | Gorczyca, Wojciech et al., <u>Terminal I</u> Cancer Research, Vol. 53, 8 (1993) 1 | | nd Nick Translation Assays, | | | |
| | AP | Albo, D. et al., Thrombospondin (TSI Human A549 Lung Carcinoma Cell P Stimulate Tumor Cell Attachment In Vol. 203, 2 (1994) 857-865 | lasminogen Activator Inhibitor | Type 1 (PA1-1) Production and | | | |
| | AQ | Robbins, Bruce A. et al., <u>Immunohist</u> <u>Solid Human Malignancies</u> , <i>Archives</i> 841-845 | | | | | |
| | AR | Albo, Daniel et al., <u>Thrombospondin-Tumor Cell Invasion through Up-Reg</u> 122, 2 (1997) 493-500 | gulation of the Plasminogen/Plas | ogen/Plasmin System, Surgery, Vol. | | | |
| | AS | Creamer, Daniel et al., Altered Vascu of Pathology, Vol. 147, 6 (1995) 166 | | ession in Psoriasis, Amer. Jour. | | | |
| | AT | Tuszynski, George P. et al., <u>The Role Angiogenesis</u> , <i>BioEssays</i> , Vol. 18, 1 (| of Thrombospondin-1 in Tumo | r Progression and | | | |
| | AU | Zabrenetzky, Vivian et al., Expression Inversely Correlates with Malignant I Lines, Intl. Journal of Cancer, Vol. 5 | n of the Extracellular Matrix Mo Progression in Melanoma, Lung | | | | |
| | AV | | ar Mediators of Angiogenesis in Bladder Cancer, Cancer | | | | |
| | AW | Wight, Thomas N. et al., Light Micro | scopic Immunolocation of Thro | | | | |
| AW Journal of Histochemistry and Cytochemistry a | | pondin Gene in the Mouse is Si | milar in Organization to | | | | |
| AY LaBell, Terry et al., Sequence and Ch cDNA: Potential Regulatory Role for 225-229 LaBell, Terry et al., Thrombospondin AZ Expression of a Second Member of the Vol. 12 (1992) 421-429 | | | the 3' Untranslated Region, Ge | enomics, Vol. 17, 1 (1993) | | | |
| | | | e Thrombospondin Gene Famil | y in Humans, Genomics, , | | | |
| | AAA | Laherty, Carol D., <u>Characterization o</u> <u>Cell Growth and Development</u> , <i>Jour</i> . | | | | | |
| | ABB | Volpert, Olga V., <u>Inhibition of Angio</u> Research Communications, Vol. 217, | | Biochemical and Biophysical | | | |
| | ACC | Panetti, T. et al., Endothelial Cell Minand Thrombospondin-2 Journal of La | togenesis induced by LPA: Inhibitogenesis induced by Inh | e, Vol. 129, 2 (1997) 208-216 - | | | |
| | ADD | Kyriakides, Themis R. et al., Mice that Abnormalities that are associated with Density, and a Bleeding Diathesis, Jo | h Disordered Collagen Fibrillog | enesis, an Increased Vascular | | | |

| Examiner Signature AddivAce | Date Consider |
|------------------------------|---------------|
| /Vami | |

red 219-02

ì

| 1,1,2 | | | | Sneet <u>3</u> of <u>3</u> | | |
|---|--------|--|------------------------------------|---|--|--|
| Substitute For (Modified) | 182 | Patent and Trademark Office | Attorney's Docket No. 10287-051001 | Application No. 09/536,087 AN 31 Group Art Unit | | |
| In | | n Disclosure Statement by Applicant | Applicant Michael Detmar et al. | JAN 3 1 | | |
| (37 CFR §1.98 | ` | veral sheets if necessary) | Filing Date March 24, 2000 | Group Art Unit | | |
| | | ocuments (include Author, 1 | Citle Date and Place | TECHCENTER 16 | | |
| Examiner | Desig. | The later than the la | inic, Bate, and i lace t | or rubiloudion) | | |
| Initial | Desig. | | Document | | | |
| midai | '' | Richard, Lisa et al., A Simple Immun | | ective Isolation and Long-Tern | | |
| \mathcal{N} | AEE | Culture of Human Dermal Microvasc Vol. 240, 1 (1998) 1-6 | | | | |
| AFF Detmar, Michael et al., Hypoxia Regi Endothelial Growth Factor (VPF/VE Dermatology, Vol. 108, 5 (1997) 263 | | | GF) and its Receptors in Huma | • | | |
| AGG Detmar, Michael et al., Increased Microvascular Density Adhesion in the Skin of VEGF Transgenic Mice, Journa (1998) 1-6 | | | | | | |
| AHH Human Epidermoid Carcinoma Cells Natl. Acad. Sci. USA, Vol. 88, 13 (19 | | | and Identification of VEGF M | | | |
| AII O'Reilly, Michael S. et al., Angiostatin Induces and Sustain Mice, Nature Medicine, Vol. 2, 6 (1996) 689-692 | | | | ncy of Human Primary Tumor | | |
| | AJJ | Yuan, Fa et al., <u>Time-dependent Vaso</u> <u>Human Tumor Xenografts Induced by</u> Permeability Factor Antibody, <i>Proc.</i> 1 | y an Anti-Vascular Endothelia | Growth Factor/Vascular | | |
| Permeability Factor Antibody, Proc. Natl. Acad. Sci. USA, Vol. 93 (1986) 14765-14770 | | | | | | |

| Examiner Signature | 1 1 | | | Date Considered | _ | | |
|---|------|---|-----|-----------------|---|--|--|
| | Noth | A | Qen | 2-19-02 | | | |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with | | | | | | | |
| next communication to applicant. | | | | | | | |